DR. GULISA TURASHVILI, M.D., PH.D.

Plain English
This research paper looks at tumors associated with mutations in the DICER1 gene, which can increase the risk of developing various gynecologic cancers. The study finds that these tumors often have certain common features and can include types like embryonal rhabdomyosarcoma and Sertoli-Leydig cell tumors. Recognizing these features can help doctors prompt genetic testing, which benefits patients by improving surveillance and management of their conditions. Who this helps: Patients and their families.

Plain English
This study looked at a rare finding called isolated squamous morular metaplasia in tissue samples taken from the lining of the uterus. Out of more than 32,000 samples, only 57 had this condition, with a low risk of developing cancer later on—about 5.4% went on to show cancer in follow-up tests. This is important because it suggests that many patients might not need repeated tests if their initial follow-up shows no signs of cancer. Who this helps: Patients with isolated squamous morular metaplasia can avoid unnecessary repeat biopsies.

Plain English
This study looked at five cases of uterine teratomas, which are rare tumors that can contain various types of tissue. The tumors ranged in size from 2.4 to 6.5 cm, and most patients were between 29 and 60 years old. While some of the tumors were benign and showed no signs of disease after follow-up of up to 42 years, two tumors had features of immaturity that could indicate a need for concern, but further research is needed to understand the potential risks associated with them. Who this helps: This research benefits doctors and researchers by providing insights into uterine teratomas, helping them better diagnose and treat these rare tumors.

Plain English
This study looked at how the type of cervical cancer—squamous cell carcinoma (SCC) or adenocarcinoma (ECA)—and whether the cancer was linked to the human papillomavirus (HPV) affected survival rates. Out of 634 patients, 84% had HPV-positive cancer, and patients with SCC were generally older and more likely to have lymph-vascular invasion but less likely to have metastases compared to those with ECA. The findings highlight that both the type of tumor and HPV status are important for predicting survival, which can help guide treatment decisions. Who this helps: This helps patients and doctors understand how cancer type and HPV status impact treatment and outcomes.

Plain English
Researchers studied a rare type of tumor called DICER1-related primitive polyphenotypic neoplasm, which can occur in the female reproductive system and abdomen. They found 15 cases of this tumor in patients aged 10 to 77, with many showing specific cell features that made them difficult to identify. Understanding these tumors is important because recognizing their unique characteristics can lead to better diagnosis and genetic testing, especially for younger patients who may have inherited risks.

Plain English
Researchers studied a type of ovarian and fallopian tube cancer with a unique appearance. They found that these tumors often lack a specific marker (PAX8) that is usually present in other cancers, but they commonly express another marker (SOX17) and have mutations in a gene (CTNNB1) that affect cell behavior. This understanding is important because it helps doctors correctly identify these tumors, preventing misdiagnosis and ensuring patients receive the right treatment.

Plain English
This study looked at how the presence and extent of lymphovascular invasion (LVI) affects the outcomes for patients with early-stage cervical squamous cell carcinoma. Researchers analyzed data from 426 patients and found that those with stage IB cancer and extensive LVI had significantly worse chances of surviving without progression (about 2.86 times worse) and overall survival (about 2.88 times worse) compared to those with little or no LVI. This is important because it suggests that measuring LVI can help doctors better predict how a patient might respond to treatment. Who this helps: Doctors and patients with early-stage cervical cancer.

Plain English
This study focused on malignant Brenner tumors (MBTs), which are rare ovarian tumors that can often be confused with other types of tumors. It found that over half of cases are diagnosed at an early stage, but nearly 20% experience recurrence or lead to death. Recognizing the specific features of MBTs is crucial for proper treatment and better patient outcomes. Who this helps: This helps patients diagnosed with ovarian tumors and their doctors by improving diagnostic accuracy and treatment choices.

Plain English
This study looked at a rare type of tumor called cellular angiofibromas (CAFs) that develop in the vulva. Researchers examined 13 cases, finding that 4 of them had unusual cell features (aCAF) and 9 showed more aggressive changes (tCAF). Most tumors were about 4.75 cm in size and occurred in women around 49 years old, with 20% of patients experiencing a recurrence of the tumor after surgery, highlighting the importance of complete removal for better outcomes. Who this helps: This research benefits patients with vulvar tumors and their doctors by improving awareness and treatment strategies for rare tumor variants.

Plain English
This study looked at different ways to measure HER2 levels in endometrial cancer, which could help decide treatments that target this protein. They found that about 31% of endometrial cancer cases were positive for HER2 using standard gynecologic and breast cancer criteria, while 35.7% were positive using gastric cancer criteria. The findings highlight how using the right scoring system can improve treatment accuracy and outcomes for patients with endometrial cancer. Who this helps: This helps patients with endometrial cancer who may benefit from targeted therapies.

Plain English
This study focused on updating guidelines for testing biomarkers in patients with gynecologic cancers, like ovarian or uterine cancer. The College of American Pathologists introduced significant changes to the testing protocol, including new markers for hormone receptors, p53 abnormalities, and PD-L1 testing, which can guide treatment decisions. These updates aim to improve clarity and usefulness of test reports, enhancing patient care. Who this helps: This benefits patients with gynecologic cancers by providing clearer and more relevant information for their treatment.

Plain English
This study examined the differences in HER2 levels in endometrial cancer, specifically looking at how HER2 is expressed within tumors. They found that 31% of patients tested positive for HER2 using specific criteria, while 42.6% were positive using different criteria. Additionally, 45.7% of tumors displayed uneven HER2 expression, which could affect treatment effectiveness. Who this helps: This helps doctors and patients with endometrial cancer in understanding treatment options based on HER2 levels.

Plain English
This study looked at a particular type of cervical cancer that isn't caused by the human papillomavirus (HPV) and compared it to the more common HPV-related cervical cancer. Researchers found that the HPV-independent cervical cancers had worse outcomes: patients were typically older (median age 68), had larger tumors, and experienced more frequent recurrences and lower survival rates compared to HPV-associated cancers. This research highlights the need for better testing and monitoring for these less common cancers, especially in older women. Who this helps: This benefits patients diagnosed with HPV-independent cervical cancer and their doctors by informing them about the severity and management of this disease.

Plain English
This study looked at a rare type of uterine tumor that has characteristics similar to Wilms tumors, which are usually found in kidneys. Researchers found that of the eight patients studied, four had specific genetic mutations (DICER1 mutations) linked to these tumors. Their findings showed that these tumors often had complex structures and various cell types, and that outcomes varied: while one patient with a non-mutated tumor died within 9 months, three patients with DICER1 mutations were still alive after more than two and a half years. Who this helps: This study helps doctors understand and better treat patients with these unusual tumors.

Plain English
Researchers studied a rare type of uterine cancer called high-grade uterine sarcoma and discovered a new gene fusion (MEIS2::FOXO4) in a patient. This finding, which hasn’t been reported before in uterine sarcomas, shows the importance of analyzing the genetic makeup of these tumors, especially when they appear unusual. Understanding these genetic changes can help improve diagnosis and treatment for patients with rare cancers.

Plain English
This paper examines the challenges and necessary updates in diagnosing endometrial carcinoma, a type of cancer affecting the lining of the uterus. It specifically addresses inconsistencies in how surgical samples are evaluated and suggests best practices for assessing these samples to improve diagnosis and treatment accuracy. By offering a clear framework for reporting and classifying the cancer, the findings aim to enhance the reliability of results, which is crucial as approximately 66% of women diagnosed with this cancer require tailored treatment plans based on accurate staging. Who this helps: This helps doctors and pathologists who diagnose and treat patients with endometrial cancer.

Plain English
This study looked at how well experienced breast cancer pathologists agree on evaluating a specific type of breast cancer known as HER2-low. The researchers found that while the agreement improved after a training session, the pathologists still had trouble consistently identifying low levels of HER2 protein, with reliability scores changing from 0.796 to 0.804 after training. This matters because accurate assessment is crucial for determining the best treatment options for patients with this type of cancer. Who this helps: This helps patients with HER2-low breast cancer by ensuring they receive the correct treatment.

Plain English
This study looked at low-grade endometrial stromal sarcoma (LGESS), a type of tumor in the uterus that can have different genetic and physical characteristics. Researchers analyzed samples from 51 patients and found that 55% of the tumors had a specific gene fusion (JAZF1::SUZ12), while 21% did not show any known genetic changes. Identifying these variations is important because it can improve diagnosis and treatment strategies for different patients with LGESS. Who this helps: Patients with low-grade endometrial stromal sarcoma and their doctors.

Plain English
This study looked at two types of rare ovarian tumors: pure Wilms tumors (WT) and those associated with teratomas. Researchers analyzed five tumors, discovering that the pure WTs had specific genetic changes (DICER1 variants) while the teratoma-associated WTs did not, indicating they are fundamentally different types of tumors. This distinction is important because it can guide better diagnosis and treatment for patients with ovarian tumors. Who this helps: This helps patients and doctors by improving understanding of ovarian tumor types.

Plain English
This study looked at a rare type of cancer called sarcoma, specifically those that have a genetic change involving RAD51B. Researchers found 8 new cases, including one that was not in the uterus, and discovered that these tumors can vary significantly in appearance and behavior. For example, they noted that 3 out of 5 patients had serious outcomes, including local recurrences and deaths linked to the disease. Who this helps: This research benefits patients diagnosed with RAD51B-rearranged sarcomas and their doctors by providing important information on this aggressive cancer type.

Plain English
Researchers looked at how well breast pathologists agree on assessing Ki-67 levels in breast cancer, which are important for understanding how aggressive the cancer might be. In their study involving six pathologists, they found that while the agreement improved with a new method, they still only reached moderate agreement when using a 20% threshold for Ki-67 levels (0.437 in the first round and 0.479 in the second round). This matters because inconsistent evaluations can affect treatment decisions for patients with breast cancer. Who this helps: Patients with breast cancer who need accurate assessments for their treatment plans.

Plain English
This study looked at how accurately breast pathologists can identify certain structures called tubules in invasive breast cancer samples, as defined by the World Health Organization. Out of 58 images analyzed, pathologists agreed with the expert professor on identifying these tubules only about 54% of the time. This matters because a significant portion of tubule structures (41%) was often missed, which could affect the diagnosis and treatment of breast cancer. Who this helps: This helps patients by improving the accuracy of breast cancer diagnoses.

Plain English
This study looked at 115 cases of rare ovarian steroid cell tumors to better understand their potential for becoming cancerous and what factors might affect patient outcomes. The researchers found that less than 10% of these tumors were clinically malignant, and while most patients had tumors that were staged I and small (median size 3 cm), some recurrences did happen several years later, with a median time to recurrence of 33 months. Key factors associated with a higher chance of recurrence included having larger tumors and more advanced staging. Who this helps: This benefits patients diagnosed with ovarian steroid cell tumors and their doctors by providing clearer risk information.

Plain English
This research paper examined different types of hardening tissue growths in the breast, which can be either noncancerous or cancerous. It found that recognizing certain specific features of these lesions is crucial for accurate diagnosis and treatment. The paper highlighted various conditions, including benign lesions like sclerosing adenosis and some cancerous types like ductal carcinoma in situ, emphasizing their features and how they can be distinguished from one another. Who this helps: This research benefits doctors and pathologists who diagnose and treat breast lesions.

Plain English
This study looked at a new way to diagnose malignant phyllodes tumors (MPTs) by comparing it to the old World Health Organization (WHO) criteria. The researchers found that using the new refined criteria, 35.7% of MPT patients experienced metastasis (spread of cancer), while none of the borderline cases (BoPTs) did. This is important because it indicates that the refined criteria are better for predicting which tumors are likely to spread, helping guide treatment decisions for patients. Who this helps: This benefits patients with phyllodes tumors by helping doctors determine the best treatment approach based on their diagnosis.

Plain English
This study examined different genetic changes in a type of cancer called endometrial stromal sarcoma (ESS). Researchers found new gene fusions in five cases, including three patients with a specific fusion (EPC1::EED) living an average of 20 months after treatment, and one patient with another fusion (ING3::PHF1) surviving 13 months post-surgery. These findings are important because they help identify different genetic profiles of ESS, which could improve diagnosis and treatment options for patients. Who this helps: This helps patients with endometrial stromal sarcoma by providing better understanding and potential treatment paths.

Plain English
The study focused on gestational trophoblastic diseases (GTD), which are rare conditions that can be benign or cancerous and arise from pregnancy tissue. It found that the incidence of one type of GTD, known as hydatidiform mole, ranges between 0.57 and 2 cases per 1,000 pregnancies, and that using ultrasound has improved the early detection of these diseases, leading to better patient outcomes. This research is important because it highlights new ways to diagnose and manage these diseases, including advancements in treatment options like immunotherapy for more severe cases. Who this helps: Patients with gestational trophoblastic diseases and their doctors.

Plain English
This study reviewed various types of inflammatory issues that can occur in breast tissue, ranging from acute infections to chronic inflammatory diseases. Researchers found that these lesions can look very different on tests, which can make diagnosis difficult. Importantly, understanding the specific features of these conditions helps pathologists provide better guidance for treatment, which is essential since most biopsies do not clearly indicate what is wrong. Who this helps: This research benefits pathologists and doctors treating patients with breast inflammation.

Plain English
This study looked at spindle cell proliferations (SCPs) found in breast tissue samples taken with a needle and whether surgery is always necessary to confirm the diagnosis. Researchers examined 197 cases and found that 53% were benign, 26% were indeterminate, and 19% were malignant. The findings showed that nearly two-thirds of excised SCPs were benign, suggesting that many patients might avoid surgery if their condition is accurately diagnosed through other tests. Who this helps: This helps patients with spindle cell proliferations in their breast tissue who may be able to avoid unnecessary surgery.

Plain English
This research focused on improving the way researchers measure how effective treatments are in neoadjuvant breast cancer clinical trials, which are trials that test treatments given before surgery. The group of experts created new guidelines that define important outcomes, like complete removal of cancer from both the breast and lymph nodes, and emphasized the need for clear and consistent measurements. This matters because having standardized definitions can help ensure more reliable comparisons between studies and ultimately improve treatment strategies for breast cancer. Who this helps: Patients with breast cancer and the doctors treating them.

Plain English
This study examined the genetic similarities between endometrioid endometrial cancer (EEC) and endometrioid ovarian cancer (EOC) when they occur at the same time in patients. Researchers found that all co-occurring EEC and EOC share a common origin, but the DNA patterns showed distinct differences between the tumors from the uterus and the ovaries. Specifically, when both cancers were present, they could influence each other's genetic characteristics, which may be important for understanding how these tumors behave and could lead to better treatments. Who this helps: This helps patients with endometrial and ovarian cancers by improving treatment strategies and understanding tumor behavior.

Plain English
This study looked at how well doctors can evaluate sentinel lymph nodes during breast cancer surgery, comparing remote assessments using telepathology with traditional on-site evaluations. Researchers analyzed data from 385 patients and found that the accuracy of remote assessments had a slightly higher discrepancy rate of 9.6% compared to 5.3% for on-site evaluations, but these differences were not statistically significant. Understanding the effectiveness of telepathology is important as it offers a modern way to make quick medical decisions during surgeries, especially as technology advances in healthcare. Who this helps: This benefits patients undergoing breast cancer surgery and their doctors.

Plain English
This study looked at how well the current guidelines for diagnosing malignant phyllodes tumors (MPTs) are working. Out of 65 cases examined, only 20% showed all five key features that the guidelines recommend, and 31% of the patients had distant metastases. The researchers found that relying only on these guidelines could miss many cases of MPTs that can spread, so they suggest new criteria that could better identify these dangerous tumors. Who this helps: Patients at risk of malignant phyllodes tumors.

Plain English
This study looked at a rare type of uterine cancer known as BCOR internal tandem duplication (ITD) associated with high-grade endometrial stromal sarcoma, by examining a case in a young woman. The researchers found specific characteristics of the tumor, such as an over 50% positivity for a protein called cyclin D1 and a low number of dividing cells, which can help doctors identify this cancer type more accurately. Understanding these features is crucial for proper diagnosis and predicting patient outcomes. Who this helps: This benefits doctors and healthcare providers who treat young women with uterine tumors.

Plain English
This study looked at how well a community program could screen women with endometrial cancer for Lynch syndrome, a genetic condition that increases cancer risk. Out of 693 new cases of endometrial cancer, 467 were eligible for the screening, and about 26% showed abnormal DNA repair that could indicate Lynch syndrome. This is important because identifying women with this condition allows for early detection of other cancers and better management of their health risks. Who this helps: This helps women with endometrial cancer, especially those under 70, by identifying those at higher risk for other cancers.

Plain English
This study looked at whether testing a specific protein (EPM2AIP1) in endometrial cancer could help identify changes (methylation) in a gene (MLH1) more easily and quickly than traditional methods. Researchers reviewed 119 cases and found that EPM2AIP1 testing matched the MLH1 methylation results in 95% of cases, showing it could serve as a quicker and simpler test. This matters because it can speed up diagnosis and potentially improve treatment decisions for patients with endometrial cancer. Who this helps: Patients with endometrial cancer.

Plain English
This research focuses on using multigene tests to help doctors make treatment decisions for patients with early-stage, invasive breast cancer. The study found that certain tests, like Oncotype DX and MammaPrint, can help identify patients who may not need chemotherapy, particularly those with low-risk results. This is important because avoiding unnecessary treatments can lead to better quality of life and lower healthcare costs. Who this helps: Patients with early-stage, hormone-positive breast cancer.

Plain English
This study looked at a type of cancer called endometrial stromal sarcoma (ESS) to understand how certain genetic changes affect its classification as low-grade or high-grade. Researchers analyzed 13 patients with specific genetic alterations, finding that their tumors were typically larger (about 9.3 cm on average) and showed aggressive growth patterns. Out of the patients monitored, 33% died from the disease, and another 25% showed signs of recurrence, suggesting these genetic changes might indicate a higher risk of severe disease. Who this helps: This information benefits doctors and pathologists in accurately diagnosing and treating patients with endometrial stromal sarcomas.

Plain English
This study looked at a specific type of uterine tumor that has unique genetic changes known as KAT6B::KANSL1 and KAT6A::KANSL1 fusions. Researchers examined 13 tumors, finding that most were diagnosed as low-grade endometrial stromal sarcomas (LG-ESS), but many showed unusual characteristics. Of the patients, 5 were disease-free after treatment, while 3 unfortunately died from the disease within a few years, highlighting that this type of tumor might behave more aggressively than previously thought, even if it doesn’t grow invasively. Who this helps: This information benefits doctors and researchers working on uterine tumors.

Plain English
This study looked at columnar cell lesions (CCLs) in breast tissue to understand their role in developing low-grade breast cancers. Researchers found that while CCLs are early changes related to these cancers, they rarely lead to invasive cancer, with upgrade rates varying widely when assessed during biopsies. Understanding CCLs helps improve how we monitor and manage early breast cancer risks, leading to better patient outcomes. Who this helps: This helps patients and doctors by clarifying the significance of early breast tissue changes.

Plain English
This study looked at a woman with a type of tumor in her uterus, originally misidentified as leiomyosarcoma but later correctly diagnosed as an inflammatory myofibroblastic tumor (IMT) due to genetic testing. After her tumor returned, she was treated with a medication called alectinib, which led to complete tumor disappearance on scans after six months, and she remained cancer-free for three years. This finding is important because it shows how genetic testing and targeted treatments can significantly improve the care and outcomes for patients with complex tumors. Who this helps: This helps patients with rare tumors and healthcare providers who treat them.

Plain English
This study looked at a rare type of uterine cancer called uterine sarcoma, specifically one case where the cancer cells had a specific genetic change known as a FGFR1-TACC1 gene fusion. The patient was a 53-year-old woman with a 6 cm tumor, and the researchers found that this gene fusion might occur more often in similar cancers, suggesting a need for more genetic testing. Understanding this gene fusion is important because it could help identify patients who might benefit from targeted treatments tailored to this genetic change. Who this helps: This benefits patients with uterine sarcoma, especially those whose tumors do not fit standard diagnostic criteria.

Plain English
This study looked at a rare type of cancer called uterine leiomyosarcoma in a 41-year-old woman who had symptoms suggesting a fibroid. After surgery, it was discovered that she had a high-grade tumor with specific genetic changes, including a new fusion gene called TRIM13-PLAG1. Unfortunately, the cancer had spread to her lungs, and she passed away shortly after her diagnosis, highlighting the aggressive nature of this tumor and the need for better understanding and treatment options. Who this helps: This research helps patients and doctors by improving diagnosis and understanding of treatment for this rare cancer type.

Plain English
This study examined two types of breast tumors—solid papillary carcinoma (SPC) and encapsulated papillary carcinoma (EPC)—by reviewing 50 cases diagnosed between 2000 and 2019. Researchers found that while only a small percentage (6.5%) of patients had a recurrence of cancer, most tumors showed signs of favorable prognosis, meaning they are generally less aggressive and often don’t spread to lymph nodes or other parts of the body. However, some SPCs were more likely to be invasive than EPCs, suggesting that they could sometimes behave like low-grade cancers despite being classified as non-invasive. Who this helps: Patients with breast tumors and their doctors.

Plain English
This study reviews updates to the World Health Organization's classification system for tumors of the ovaries and fallopian tubes, which was updated in 2020. While most classifications remained unchanged, the researchers highlighted key improvements in categorizing different types of tumors, including serous and non-serous epithelial tumors and sex cord-stromal tumors. These updates are important because they help doctors better identify and treat these tumors, leading to improved patient care. Who this helps: This benefits patients and doctors involved in diagnosing and treating ovarian and fallopian tube tumors.

Plain English
This study looked at a rare type of uterine tumor that has a specific genetic feature called an AFF1 fusion. Over 15 years, the tumor's complicated nature led to confusion in diagnosing it, highlighting that traditional methods alone are not enough to predict how it will behave or respond to treatment. By using advanced genetic testing, researchers found this fusion, which could help improve how doctors diagnose and treat similar tumors in the future. Who this helps: This helps patients with uterine tumors and their doctors.